var data={"title":"Alteplase: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Alteplase: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5595?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">see &quot;Alteplase: Drug information&quot;</a> and <a href=\"topic.htm?path=alteplase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Alteplase: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132252\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Activase;</li>\n      <li>Cathflo Activase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132253\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Activase rt-PA;</li>\n      <li>Cathflo Activase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050935\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Thrombolytic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Thrombotic Occlusion (Central Venous Catheter), Treatment Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11431468\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Occluded IV catheter:</b> Intracatheter: <b>Dose listed is per lumen; for multilumen catheters, treat one lumen at a time; do not infuse into patient; dose should always be aspirated out of catheter after dwell.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Manufacturer's labeling: Central venous catheter: Use a 1 mg/mL concentration; instill a volume equal to 110% of the internal lumen volume of the catheter; do not exceed 2 mg in 2 mL; leave in lumen for up to 2 hours, then aspirate out of catheter; may instill a second dose if catheter remains occluded after 2-hour dwell time</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alternate dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Chest</i> guidelines (Monagle 2008): Limited data available: Central venous catheter: 0.5 mg diluted in NS to a volume equal to the internal volume of the lumen; instill in lumen over 1 to 2 minutes; leave in lumen for 1 to 2 hours, then aspirate out of catheter; flush catheter with NS. <b>Note:</b> The most recent guidelines (2012) continue to recommend alteplase as a treatment option but specific dosage recommendation is not provided (Monagle 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Soylu, 2010: Limited data available: Central venous catheter: 0.25 to 0.5 mg/mL solution; instill a volume to fill the catheter; leave in lumen for up to 2 hours, then aspirate out of catheter; dosing described in trial of 18 neonates including four patients with GA &le;32 weeks </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Systemic thrombosis:</b> <b>Note:</b> Dose must be titrated to effect. No pediatric studies have compared local to systemic thrombolytic therapy; therefore, there is no evidence to suggest that local infusions are superior. The pediatric patients' small vessel size may increase the chance of local damage to blood vessels and formation of a new thrombus; however, local infusion may be appropriate for catheter-related thrombosis if the catheter is already in place (Monagle 2012). Various &quot;low-dose&quot; regimens have been used, both with local (or regional) and systemic administration. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Standard dose infusion:</span> IV: <b>Note:</b> The optimal dose for various thrombotic conditions is not established; most published papers consist of case reports and series; few prospective neonatal studies have been conducted; dose must be titrated to effect (eg, fibrinogen &gt;100 to 150 mg/dL). Administration of FFP may be considered prior to dose infusion. Current <i>Chest</i> guidelines recommend use  only when major vessel occlusion is causing critical compromise of organs or limbs in the neonate (Monagle, 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Chest</i> guidelines (Monagle 2012): Limited data available: Usual dose: 0.5 mg/kg/<b>hour</b> for 6 hours; reported range: 0.1 to 0.6 mg/kg/<b>hour</b>; some patients may require longer or shorter duration of therapy. Higher doses may be associated with an increased incidence of serious bleeding (Monagle 2008; Monagle 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Additional reported standard dose regimens: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>No loading dose regimens:</i> Very limited data available: Seven neonates (GA: 24 to 38 weeks) with arterial thrombosis received a continuous IV infusion of 0.1 mg/kg/<b>hour</b> initially; infusion rate was titrated to maintain fibrinogen levels &gt;100 mg/dL; dosage increases were made in 0.1 mg/kg/<b>hour</b> increments every 6 hours to a maximum of 0.4 mg/kg/<b>hour</b>; no heparin was used in these patients (Weiner, 1998). In case series of three neonates (GA: 26 to 36 weeks) with infective endocarditis and intracardiac thrombosis, a daily intermittent infusion of 0.2 mg/kg/<b>hour</b> over 6 hours for 5 days was used (Anderson, 2009). </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">\n      <i>Loading dose regimens:</i> Limited data available; dosage reported varies widely: One trial of 16 neonates used a loading dose of 0.1 mg/kg over 10 minutes, followed by an intermittent infusion of 0.3 mg/kg/<b>hour</b> infusion for 3 hours every 12 to 24 hours as determined by response and monitoring parameters; a maximum of 4 additional intermittent doses were allowed; heparin was held during alteplase infusion (Farnoux, 1998). In another trial, a loading dose of 0.7 mg/kg bolus over 30 to 60 minutes was used followed by continuous IV infusion at an initial rate of 0.2 mg/kg/<b>hour</b> for 1 to 4 days in 13 neonates (GA: 27 to 42 weeks) with catheter-related thrombosis (used in conjunction with heparin infusion); reported effective range: 0.1 to 0.3 mg/kg/<b>hour</b> (Hartmann 2001). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Low dose infusion:</span>  Very limited data available: Initial dose: IV:  0.02 to 0.03 mg/kg/<b>hour</b>, titrate dose based on patient response, range reported 0.01 to 0.06 mg/kg/<b>hour</b>; duration of therapy based on patient response. A trial comparing standard-dose and low-dose alteplase in pediatric patients  included  five neonates (four preterm; PNA 1 to 14 days) with acute thrombus in low-dose group; dosing in neonates was initiated at 0.03 mg/kg/<b>hour</b>, in three neonates receiving systemic therapy, the effective dose was 0.03 mg/kg/<b>hour</b> in one patient and 0.06 mg/kg/<b>hour</b> in the other two patients; the remaining two neonates received local infusions and required a higher infusion rate (0.1 mg/kg/<b>hour</b> and  0.24 mg/kg/<b>hour</b>); duration of therapy ranged from 48 to 70 hours; complete clot resolution occurred in all patients.  One preterm neonate with staphylococcal sepsis experienced a subdural bleed at the dose of 0.24 mg/kg/<b>hour</b> (Wang, 2003). One case series of four neonates and infants (PNA: 25 to 43 days, 2 preterm) with caval thrombosis due to central line reported using 0.02 to 0.1 mg/kg/<b>hour</b> with mixed results; resolution of clot occurred in only two patients (Anderson 1991).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050928\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">see &quot;Alteplase: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Occluded IV catheters:</b> Infants, Children, Adolescents: Intracatheter: <b>Dose listed is per lumen; for multilumen catheters, treat one lumen at a time; do not infuse into patient; dose should always be aspirated out of catheter after dwell. </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Central venous catheter: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients &lt;30 kg: Use a 1 mg/mL concentration; instill a volume equal to 110% of the internal lumen volume of the catheter; do not exceed 2 mg in 2 mL; may instill a second dose if catheter remains occluded after 2-hour dwell time </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients &ge;30 kg: 2 mg in 2 mL; may instill second dose if catheter remains occluded after 2-hour dwell time </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chest</i> guidelines (Monagle 2008): <b>Note:</b> The most recent guidelines (2012) continue to recommend alteplase as a treatment option but specific dosage recommendation is not provided (Monagle 2012)  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Central venous catheter: <b>Note:</b> Some institutions use lower doses (eg, 0.25 mg/0.5 mL) in infants 1 to &lt;3 months </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients &le;10 kg: 0.5 mg diluted in NS to a volume equal to the internal volume of the lumen; instill in lumen over 1 to 2 minutes; leave in lumen for 1 to 2 hours, then <b>aspirate out of catheter, do not infuse into patient;</b> flush catheter with NS.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients &gt;10 kg: 1 mg in 1 mL of NS; use a volume equal to the internal volume of the lumen; maximum: 2 mg in 2 mL per lumen; instill in each lumen over 1 to 2 minutes; leave in lumen for 1 to 2 hours; then <b>aspirate out of catheter, do not infuse into patient;</b> flush catheter with NS </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">SubQ port: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients &le;10 kg: 0.5 mg diluted with NS to 3 mL </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients &gt;10 kg: 2 mg diluted with NS to 3 mL </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Systemic thrombosis:  Note:</b> Dose must be titrated to effect. No pediatric studies have compared local to systemic thrombolytic therapy; therefore, there is no evidence to suggest that local infusions are superior. The pediatric patients' small vessel size may increase the chance of local damage to blood vessels and formation of a new thrombus; however, local infusion may be appropriate for catheter-related thromboses if the catheter is already in place (Monagle 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <span style=\"text-decoration: underline\">Standard dose infusion:</span> Limited data available; optimal dose not established; most published papers consist of case reports; few prospective pediatric studies have been conducted; several studies have used the following doses (Levy 1991; Weiner 1998): Infants, Children, and Adolescents: <i>Chest</i> 2012 and AHA 2013 recommendations: IV: Usual dose: 0.5 mg/kg/<b>hour</b> for 6 hours; range: 0.1 to 0.6 mg/kg/<b>hour</b>; some patients may require longer or shorter duration of therapy; higher doses may be associated with an increased incidence of serious bleeding (Giglia 2013; Monagle 2008; Monagle 2012). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <span style=\"text-decoration: underline\">Low-dose infusion:</span> Limited data available.  Various &ldquo;low-dose&rdquo; regimens have been used:  Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>AHA 2013 recommendations:</i> IV: 0.03 to 0.06 mg/kg/<b>hour</b> for 12 to 48 hours; maximum hourly dose: 2 mg/hour (Giglia 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Additional reported regimens:</i> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Wang 2003: Initial: 0.01 to 0.03 mg/kg/<b>hour</b>; usual effective range: 0.015 to 0.03 mg/kg/<b>hour</b>; duration of therapy based on clinical response; in this study of 17 pediatric patients (1.5 to 18 years) with acute and chronic thrombus, dosing was titrated to effect up to 0.06 mg/kg/<b>hour</b> in children and adolescents; final effective range: 0.007 to 0.06 mg/kg/<b>hour</b>; administration included systemic therapy as well as local infusions directly at site of thrombus (n=4); duration of therapy ranged from 4 to 96 hours.  A similar dosing range has been reported in pediatric case reports (Doyle 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Leary 2010: Initial: 0.03 to 0.06 mg/kg/<b>hour</b> for 12 to 48 hours; doses were titrated as necessary up to 0.12 mg/kg/<b>hour</b>; dosing from a retrospective study of 23 patients (median age: 12 years, range: 6 months to 21.5 years) diagnosed with DVT; eight patients required a dose increase to 0.12 mg/kg/<b>hour</b>; overall response rate: 59%, with complete clot resolution in 18% and partial resolution in 41%   </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Bratincs&aacute;k 2013:  Initial: 0.05 mg/kg/<b>hour</b> for 30 minutes, if no signs of bleeding, rate increased to 0.1 mg/kg/<b>hour</b>; therapy used in 12 children with arterial or femoral vascular occlusions following cardiac catheterization    </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <span style=\"text-decoration: underline\">Catheter-directed infusion:</span> Limited data available: Children and Adolescents: Intra-arterial, IV (administered through catheter or via catheter with tip placed at anatomic site of clot):  0.025 mg/kg/<b>hour</b> or 0.5 to 2 <b>mg/hour</b> for 12 to 24 hours (Giglia 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Parapneumonic effusion:</b> Limited data available: Infants &gt;3 months, Children, and Adolescents: Intrapleural:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dose: 4 mg in 40 mL NS, first dose at time of chest tube placement with 1-hour dwell time, repeat every 24 hours for 3 days (total of 3 doses) (Bradley 2011; St. Peter 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed: 0.1 mg/kg (maximum: 3 mg) in 10 to 30 mL NS, first dose after chest tube placement, 0.75- to 1-hour dwell time, repeat every 8 hours for 3 days (total of 9 doses) (Bradley 2011; Hawkins 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ST-elevation myocardial infarction (STEMI):</b> IV (Activase): <b>Note:</b> Manufacturer's labeling recommends 3-hour infusion regimen; however, accelerated regimen preferred by the ACCF/AHA (O&rsquo;Gara 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Accelerated regimen (weight-based): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patients &le;67 kg:</i> Infuse 15 mg IV bolus over 1 to 2 minutes followed by infusions of 0.75 mg/kg (not to exceed 50 mg) over 30 minutes then 0.5 mg/kg (not to exceed 35 mg) over 1 hour; maximum total dose: 100 mg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patients &gt;67 kg:</i> Total dose: 100 mg over 1.5 hours; administered as a 15 mg IV bolus over 1 to 2 minutes followed by infusions of 50 mg over 30 minutes, then 35 mg over 1 hour; maximum total dose: 100 mg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> <b>Thrombolytic should be administered within 30 minutes of hospital arrival.</b> Generally, there is only a small trend for benefit of therapy after a delay of 12 to 24 hours from symptom onset, but thrombolysis may be considered for selected patients with ongoing ischemic pain and extensive ST elevation; however, primary PCI is preferred in these patients. Administer concurrent aspirin, clopidogrel, and anticoagulant therapy (ie, unfractionated heparin, enoxaparin, or fondaparinux) with alteplase (O&rsquo;Gara 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute massive or submassive pulmonary embolism (PE):</b> IV (Activase): 100 mg over 2 hours; may be administered as a 10 mg bolus followed by 90 mg over 2 hours as was done in patients with submassive PE (Konstantinides 2002). <b>Note:</b> Not recommended for submassive PE with minor RV dysfunction, minor myocardial necrosis, and no clinical worsening or low-risk PE (ie, normotensive, no RV dysfunction, normal biomarkers) (Jaff 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute ischemic stroke:</b> IV (Activase): Within 3 hours of the onset of symptom onset  <b>or</b> within 3 to 4.5 hours of symptom onset (Hacke 2008; Jauch 2013): <b>Note:</b> Perform noncontrast-enhanced CT or MRI prior to administration. Initiation of anticoagulants (eg, heparin) or antiplatelet agents (eg, aspirin) within 24 hours after starting alteplase is not recommended; however, initiation of aspirin within 24 to 48 hours after stroke onset is recommended (Jauch, 2013). Initiation of SubQ heparin (&le;10,000 units) or equivalent doses of low molecular weight heparin for prevention of DVT during the first 24 hours of the 3 to 4.5 hour window trial did not increase incidence of intracerebral hemorrhage (Hacke 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recommended total dose: 0.9 mg/kg (maximum total dose: 90 mg) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patients &le;100 kg:</i> Load with 0.09 mg/kg (10% of 0.9 mg/kg dose) as an IV bolus over 1 minute, followed by 0.81 mg/kg (90% of 0.9 mg/kg dose) as a continuous infusion over 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patients &gt;100 kg:</i> Load with 9 mg (10% of 90 mg) as an IV bolus over 1 minute, followed by 81 mg (90% of 90 mg) as a continuous infusion over 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Central venous catheter clearance:</b> Intracatheter (Cathflo Activase 1 mg/mL): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients &lt;30 kg:</i> 110% of the internal lumen volume of the catheter, not to exceed 2 mg/2 mL; retain in catheter for 0.5 to 2 hours; may instill a second dose if catheter remains occluded </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Patients &ge;30 kg:</i> 2 mg (2 mL); retain in catheter for 0.5 to 2 hours; may instill a second dose if catheter remains occluded </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132234\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cathflo Activase: 2 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Activase: 50 mg (1 ea); 100 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132219\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050939\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intracatheter: CathFlo Activase: Instill the appropriate dose into the occluded catheter; do not force solution into catheter; leave in lumen; evaluate catheter function (by attempting to aspirate blood) after 30 minutes; if catheter is functional, aspirate 4 to 5 mL of blood out of catheter in patients &ge;10 kg or 3 mL in patients &lt;10 kg to remove drug and residual clot, then gently flush catheter with NS; if catheter is still occluded, leave alteplase in lumen and evaluate catheter function after 120 minutes of dwell time; if catheter is functional, aspirate 4 to 5 mL of blood out of catheter in patients &ge;10 kg or 3 mL in patients &lt;10 kg and gently flush with NS; if catheter remains occluded after 120 minutes of dwell time, a second dose may be instilled by repeating the above administration procedure. Discard any unused solution (solution does not contain preservatives). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Activase: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bolus: Bolus dose may be readied using one of the following methods: 1) Remove bolus dose from reconstituted vial using syringe and needle; for 50 mg vial: Do not prime syringe with air, insert needle into vial stopper; for 100 mg vial, insert needle away from puncture mark created by transfer device; 2) Remove bolus dose from a port on the infusion line after priming; 3) Program an infusion pump to deliver the bolus at the beginning of the infusion. Administer over 1 minute followed by infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infusion: Remaining dose for STEMI, AIS, or total dose for acute pulmonary embolism may be administered as follows: Any quantity of drug not to be administered to the patient must be removed from vial(s) prior to administration of remaining dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">50 mg vial: Use polyvinyl chloride IV bag or glass vial and infusion set</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">100 mg vial: Use same puncture site made by transfer device to insert spike end of infusion set and infuse from vial</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">May also be further diluted in NS or D<sub>5</sub>W if desired. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intrapleural: Instill dose into chest tube at time of chest tube placement and clamp drain. Although the optimum dwell time has not been determined, clinical trials more often have used either a 45 minute (Hawkins 2004) or 1 hour (Rahman 2011; St. Peter 2009) dwell time; after dwell period, release clamp and connect chest tube to continuous suction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471278\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 0.5 mg/mL <b>or</b> 1 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132245\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Activase: Store intact vials at room temperature (not to exceed 30&deg;C [86&deg;F]), or under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light. Store reconstituted solution at 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F) and use within 8 hours. Discard any unused solution</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cathflo Activase: Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); protect from light. Store reconstituted solution at 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F) and use within 8 hours. Discard any unused solution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solutions of 0.5 mg/mL, 1 mg/mL, and 2 mg/mL in SWI retained &ge;94% of fibrinolytic activity at 48 hours when stored at 2&deg;C in plastic syringes; these solutions retained &ge;90% of fibrinolytic activity when stored in plastic syringes at -25&deg;C or -70&deg;C for 7 or 14 days, thawed at room temperature and then stored at 2&deg;C for 48 hours (Davis 2000). Solutions of 1 mg/mL in SWI were stable for 22 weeks in plastic syringes when stored at -30&deg;C and for &sim;1 month in glass vials when stored at -20&deg;C; bioactivity remained unchanged for 6 months in propylene containers when stored at -20&deg;C and for 2 weeks in glass vials when stored at -70&deg;C (Generali 2001). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050938\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Activase: Thrombolytic agent used in treatment of acute MI, acute ischemic stroke, and acute massive pulmonary embolism (All indications: FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CathFlo Activase: Treatment of occluded central venous access devices (catheters) to restore function (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132309\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Activase may be confused with Cathflo Activase, TNKase</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alteplase may be confused with Altace</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&ldquo;tPA&rdquo; abbreviation should not be used when writing orders for this medication; has been misread as TNKase (tenecteplase)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132306\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all drugs that may affect hemostasis, bleeding is the major adverse effect associated with alteplase. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the dosage administered, concurrent use of multiple agents that alter hemostasis, and patient predisposition. Rapid lysis of coronary artery thrombi by thrombolytic agents may be associated with reperfusion-related atrial and/or ventricular arrhythmia. Lowest rate of bleeding complications expected with dose used to restore catheter function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Gastric ulcer with hemorrhage, gastrointestinal hemorrhage, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Genitourinary tract hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic&amp; oncologic: Bruise, hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Catheter site hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angioedema (orolingual), epistaxis, gingival hemorrhage, hypersensitivity reaction (including anaphylaxis, anaphylactoid reaction, laryngeal edema, skin rash, urticaria), intracranial hemorrhage (when adult dose is &le;100 mg), retroperitoneal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional events associated with use in STEMI: Asystole, atrioventricular block, atrioventricular dissociation, bradycardia, cardiac failure, cardiac tamponade, cardiogenic shock, ischemia (recurrent), mitral valve insufficiency, myocardial reinfarction, myocardial rupture, pericardial effusion, pericarditis, pulmonary edema, seizure, thromboembolism, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional events associated with use in pulmonary embolism: Pleural effusion, pulmonary edema, pulmonary embolism (re-embolization), thromboembolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional events associated with use in stroke: Cerebral edema, cerebral herniation, cerebrovascular accident (new ischemic stroke), seizure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132240\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to alteplase or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Treatment of STEMI or PE:</b> Active internal bleeding; history of recent stroke; recent (within 3 months [ACCF/AHA: Within 2 months]) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding (eg, intracranial neoplasm, arteriovenous malformation, aneurysm); known bleeding diathesis; severe uncontrolled hypertension (ACCF/AHA: Unresponsive to emergency therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Additional absolute contraindications (ACCF/AHA [O&rsquo;Gara 2013]; Kearon 2012; Kearon 2016):</i> Active bleeding (excluding menses); any prior intracranial hemorrhage; suspected aortic dissection; ischemic stroke within 3 months <b>except</b> when within 4.5 hours; significant closed head or facial trauma within 3 months with radiographic evidence of bony fracture or brain injury</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Treatment of AIS:</b> Current intracranial hemorrhage; subarachnoid hemorrhage; active internal bleeding; recent (within 3 months) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding (eg, intracranial neoplasm, arteriovenous malformation, aneurysm); known bleeding diathesis; severe uncontrolled hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Additional contraindications (AHA/ASA [Jauch 2013]):</i> History of intracranial hemorrhage; suspicion of subarachnoid hemorrhage; stroke within 3 months; arterial puncture at a noncompressible site in previous 7 days; uncontrolled hypertension at time of treatment (eg, &gt;185 mm Hg systolic or &gt;110 mm Hg diastolic); multilobar cerebral infarction (hypodensity &gt;<sup>1</sup>/<sub>3</sub> cerebral hemisphere); known bleeding diathesis including but not limited to current use of oral anticoagulants with an INR &gt;1.7 (or PT &gt;15 seconds), current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive laboratory tests (eg, aPTT, INR, ECT, TT, or appropriate factor Xa activity assays) (See &ldquo;<b>Note</b>&rdquo;), administration of heparin within 48 hours preceding the onset of stroke with an elevated aPTT greater than the upper limit of normal, or platelet count &lt;100,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The AHA/ASA 2013 guidelines do allow the use of alteplase in patients taking direct thrombin inhibitors (eg, dabigatran) or direct factor Xa inhibitors (eg, rivaroxaban) when sensitive laboratory tests (eg, aPTT, INR, ECT, TT, or appropriate direct factor Xa activity assays) are normal or the patient has not received a dose of these agents for &gt;2 days (assuming normal renal function) (Jauch 2013). The AHA/ASA 2016 scientific statement states that alteplase is not recommended in patients who have received LMWH treatment doses within the previous 24 hours (AHA/ASA [Demaerschalk 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Additional exclusion criteria within clinical trials:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Presentation &lt;3 hours after initial symptoms (NINDS, 1995): Time of symptom onset unknown, rapidly improving or minor symptoms, major surgery within 2 weeks, GI or urinary tract hemorrhage within 3 weeks, aggressive treatment required to lower blood pressure, glucose level &lt;50 or &gt;400 mg/dL, and lumbar puncture within 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The AHA/ASA 2016 scientific statement recommends alteplase use in patients presenting &lt;3 hours after initial symptoms with mild but disabling stroke symptoms in the opinion of the treating physician. Alteplase is also reasonable in patients presenting &lt;3 hours after initial symptoms with moderate-to-severe ischemic stroke who demonstrate early improvement, but remain moderately impaired and potentially disabled in the examiner's judgment (AHA/ASA [Demaerschalk 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Presentation 3 to 4.5 hours after initial symptoms (AHA/ASA [Jauch 2013]; ECASS-III; Hacke 2008; Powers 2015): Age &gt;80 years, time of symptom onset unknown, rapidly improving or minor symptoms, current use of oral anticoagulants regardless of INR, glucose level &lt;50 or &gt;400 mg/dL, aggressive intravenous treatment required to lower blood pressure, major surgery or severe trauma within 3 months, baseline National Institutes of Health Stroke Scale (NIHSS) score &gt;25 [ie, severe stroke], and history of both stroke and diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The AHA/ASA 2016 scientific statement has provided updated evidence on certain patients presenting in the 3 to 4.5 hour after initial symptoms window excluded in the aforementioned earlier guidelines, including: patients &gt;80 years (alteplase use in the 3 to 4.5 window can be safe and as effective as younger patients); patients taking warfarin with an INR &lt;1.7 (alteplase use appears safe and may be beneficial); patients with a history of both stroke and diabetes (alteplase use may be as effective as treatment in the 0 to 3 hour window, and may be a reasonable option) (AHA/ASA [Demaerschalk 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132223\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: Coronary thrombolysis may result in reperfusion arrhythmias (eg, accelerated idioventricular rhythm) (Miller 1986).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Internal bleeding (intracranial, retroperitoneal, gastrointestinal, genitourinary, respiratory) or external bleeding, especially at arterial and venous puncture, sites may occur (may be fatal). The total dose should not exceed 90 mg for acute ischemic stroke or 100 mg for acute myocardial infarction or pulmonary embolism. Doses &ge;150 mg associated with significantly increased risk of intracranial hemorrhage compared to doses &le;100 mg. Bleeding risk is low. Monitor all potential bleeding sites; if serious bleeding occurs, the infusion of alteplase and any other concurrent anticoagulants (eg, heparin) should be stopped.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholesterol embolization: Has been reported rarely in patients treated with thrombolytic agents; may present with livedo reticularis, &ldquo;purple toe&rdquo; syndrome, acute renal failure, gangrenous digits, hypertension, pancreatitis, myocardial infarction, cerebral infarction, spinal cord infarction, retinal artery occlusion, bowel infarction, or rhabdomyolysis and can be fatal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orolingual angioedema: Although typically mild and transient, orolingual angioedema has occurred during and up to 2 hours after alteplase infusion in patients treated for AIS and STEMI. The use of concomitant ACE inhibitors and strokes involving the insular and frontal cortex are associated with an increased risk (Foster-Goldman 2013). The manufacturer recommends monitoring patients during and for several hours after infusion for orolingual angioedema. If angioedema develops, discontinue the infusion and promptly institute appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions that increase bleeding risk: For the following conditions, the risk of bleeding is higher with use of thrombolytics and should be weighed against the benefits of therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>&bull; PE: </i>Systolic BP &gt;180 mm Hg or diastolic BP &gt;110 mm Hg; recent bleeding (nonintracranial); recent surgery or invasive procedure; ischemic stroke &gt;3 months previously; anticoagulated (eg, VKA therapy); traumatic CPR; pericarditis or pericardial fluid; diabetic retinopathy; age &gt;75 years of age; low body weight (&lt;60 kg); female; black race (Kearon 2012; Kearon 2016); lumbar puncture within 10 days (ASRA [Horlocker 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>&bull; STEMI: </i>History of chronic, severe, poorly controlled hypertension; significant hypertension on presentation (systolic BP &gt;180 mm Hg or diastolic BP &gt;110 mm Hg); history of prior ischemic stroke &gt;3 months; dementia; traumatic or prolonged CPR (&gt;10 minutes); major surgery (&lt;3 weeks); recent internal bleeding (within 2 to 4 weeks); noncompressible vascular punctures; active peptic ulcer; oral anticoagulant therapy (ACCF/AHA [O&rsquo;Gara 2013]); lumbar puncture within 10 days (ASRA [Horlocker 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; End-stage renal disease: In the treatment of AIS, according to the AHA/ASA 2016 scientific statement, alteplase use is recommended in patients with end-stage renal disease on hemodialysis who have a normal aPTT (very limited populations evaluated). Patients with an elevated aPTT may have an increased risk for hemorrhagic complications (AHA/ASA [Demaerschalk 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ST-elevation myocardial infarction (STEMI): Appropriate use: Follow standard management for STEMI while infusing alteplase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stroke: Appropriate use: Patients who present <b>within 3 hours</b> of stroke symptom onset should be treated with alteplase unless contraindications exist. A longer time window (<b>3 to 4.5 hours</b> after symptom onset) has been shown to be safe and efficacious for select individuals who meet ECASS III criteria (AHA/ASA [Demaerschalk 2016]; AHA/ASA [Jauch 2013]; Hacke 2008; Powers 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulants: Use with caution in patients receiving oral anticoagulants; increased risk of bleeding. According to the AHA/ASA 2013 guidelines, in the treatment of acute ischemic stroke (AIS) within 3 hours of symptom onset, the current use of oral anticoagulants producing an INR &gt;1.7, direct thrombin inhibitors, or direct factor Xa inhibitors with elevated sensitive laboratory test are contraindications. However, alteplase may be administered to patients with AIS having received direct thrombin inhibitors (eg, dabigatran) or direct factor Xa inhibitors (eg, rivaroxaban) when sensitive laboratory tests (eg, aPTT, INR, platelet count, ECT, TT, or appropriate direct factor Xa activity assays) are normal or the patient has not received a dose of these agents for &gt;2 days (assuming normal renal function). When treating AIS 3 to 4.5 hours after symptom onset, the use of alteplase should be avoided with current use of any oral anticoagulant regardless of INR (AHA/ASA [Jauch 2013]). However, according to the AHA/ASA 2016 scientific statement, when treating AIS 3 to 4.5 hours after symptom onset, the use of alteplase appears safe and may be beneficial for patients taking warfarin with an INR &lt;1.7 (AHA/AHA [Demaerschalk 2016]). In the treatment of STEMI, adjunctive use of parenteral anticoagulants (eg, enoxaparin, heparin, or fondaparinux) is recommended to improve vessel patency and prevent reocclusion and may also contribute to bleeding; monitor for bleeding (ACCF/AHA [O&rsquo;Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aspirin: In the treatment of acute ischemic stroke, avoid aspirin for 24 hours following administration of alteplase; administration within 24 hours increases the risk of hemorrhagic transformation. According to the AHA/ASA 2016 scientific statement, alteplase is recommended for patients taking antiplatelet drug monotherapy or antiplatelet combination therapy (eg, aspirin and clopidogrel) before stroke on the basis that the benefit outweighs a possible small increased risk of symptomatic intracerebral hemorrhage (sICH) (AHA/AHA [Demaerschalk 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heparin or low molecular weight heparin: Concurrent heparin anticoagulation may contribute to bleeding. In the treatment of acute ischemic stroke, concurrent use of anticoagulants was not permitted during the initial 24 hours of the &lt;3 hour window trial (NINDS 1995). The AHA/ASA does not recommend initiation of anticoagulant therapy within 24 hours of treatment with alteplase (AHA/ASA [Jauch 2013]). Initiation of SubQ heparin (&le;10,000 units) or equivalent doses of low molecular weight heparin for prevention of DVT during the first 24 hours of the 3 to 4.5 hour window trial was permitted and did not increase the incidence of intracerebral hemorrhage (Hacke 2008). Alteplase use is not recommended for acute ischemic stroke in patients who have received a treatment dose of LMWH within the previous 24 hours (AHA/ASA [Demaerschalk 2016]). For acute PE, withhold heparin during the 2-hour infusion period.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in patients with advanced age (eg, &gt;75 years); increased risk of bleeding. In the treatment of pulmonary embolism, age &gt;75 years is considered a relative contraindication (Kearon 2012; Kearon 2016). In the treatment of acute ischemic stroke (within 3 to 4.5 hours after symptom onset), alteplase use in patients &gt;80 years is considered an exclusion criteria (AHA/ASA [Jauch 2013]; Hacke 2008). However, according to the AHA/ASA 2016 scientific statement, alteplase use in patients &gt;80 years with acute ischemic stroke presenting within 3 to 4.5 hours after symptom onset is safe and can be as effective as in younger patients (AHA/ASA [Demaerschalk 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: Use with caution in pregnancy; increased risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cathflo Activase: When used to restore catheter function, use Cathflo cautiously in those patients with known or suspected catheter infections. Evaluate catheter for other causes of dysfunction before use. Avoid excessive pressure when instilling into catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Intramuscular injections and nonessential handling of the patient should be avoided. Venipunctures should be performed carefully and only when necessary. Avoid internal jugular and subclavian venous punctures. If arterial puncture is necessary, use an upper extremity vessel that can be manually compressed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Alteplase has not been shown to adequately treat underlying deep vein thrombosis in patients with PE. Consider the possible risk of re-embolization due to the lysis of underlying deep venous thrombi in this setting.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819738\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Significant bleeding complications including neonatal IVH and hemorrhage requiring PRBC transfusion have been reported in pediatric patients receiving systemic tPA therapy for thrombolysis (Monagle, 2012; Weiner, 1998). Failure of thrombolytic agents in newborns/neonates may occur due to the low plasminogen concentrations (&sim;50% to 70% of adult levels); supplementing plasminogen (via administration of fresh frozen plasma) may possibly help.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298716\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132228\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13363&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.  Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.  Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Thrombolytic Agents may enhance the anticoagulant effect of Desirudin.  Management: Discontinue treatment with thrombolytic agents prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Thrombolytic Agents. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: May decrease the serum concentration of Alteplase.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: Thrombolytic Agents may enhance the adverse/toxic effect of Prostacyclin Analogues. Specifically, the antiplatelet effects of prostacyclin analogues may lead to an increased risk of bleeding when combined with thrombolytic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132230\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7872251\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. The risk of bleeding may be increased in pregnant women. Outcome information is available following alteplase use in pregnancy (Hirano 2013; Leonhardt 2006; Li 2012; &Ouml;zkan 2013). Currently, most guidelines consider pregnancy to be a relative contraindication for its use (ACCF/AHA [O&rsquo;Gara 2013]; AHA/ASA [Jauch 2013]; Kearon 2012; Kearon 2016; O'Connor 2010). Alteplase should not be withheld from pregnant women in life-threatening situations but should be avoided when safer alternatives are available (Bates 2012; Leonhardt 2006; Li 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050934\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Systemic use: Blood pressure; CBC, reticulocyte, platelet count; fibrinogen level, plasminogen, fibrin/fibrinogen degradation products, PT, PTT, signs of bleeding </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intracatheter use: Catheter function (by attempting to aspirate blood); signs of sepsis, GI bleeding, bleeding at injection site, and venous thrombosis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132222\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Initiates local fibrinolysis by binding to fibrin in a thrombus (clot) and converts entrapped plasminogen to plasmin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132239\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: &gt;50% present in plasma cleared ~5 minutes after infusion terminated, ~80% cleared within 10 minutes; fibrinolytic activity persists for up to 1 hour after infusion terminated (Semba 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub> (initial): Approximates plasma volume</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Initial: 5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Clearance (in patients with acute MI receiving accelerated regimen): Rapidly from circulating plasma (572 &plusmn; 132 mL/minute) (Tanswell 1992), primarily hepatic; &gt;50% present in plasma is cleared within 5 minutes after the infusion is terminated, ~80% cleared within 10 minutes (Semba 2000)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050943\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Activase and CathFlo Activase also contain L-arginine and phosphoric acid (for pH adjustment). Advantages of alteplase include: Low immunogenicity, short half-life, direct activation of plasminogen, and a strong and specific affinity for fibrin.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322973\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Activase Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $5,280.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $10,560.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cathflo Activase Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (1): $183.67</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132242\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actilyse (AE, AR, AT, AU, BD, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JO, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Activacin (JP);</li>\n      <li>Aktylize (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Activase (alteplase) [prescribing information]. South San Francisco, CA: Genentech, Inc; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson BJ, Keeley SR, and Johnson ND, &ldquo;Caval Thrombolysis in Neonates Using Low Doses of Recombinant Human Tissue-Type Plasminogen Activator,&rdquo; <i>Anaesth Intensive Care</i>, 1991, 19(1):22-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/1901463/pubmed\" target=\"_blank\" id=\"1901463\">1901463</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson B, Urs P, Tudehope D, et al, &quot;The Use of Recombinant Tissue Plasminogen Activator in the Management of Infective Intracardiac Thrombi in Pre-term Infants With Thrombocytopaenia,&quot; <i>J Paediatr Child Health</i>, 2009, 45(10):598-601.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/19825023/pubmed\" target=\"_blank\" id=\"19825023\">19825023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andrew M, Brooker L, Leaker M, et al, &ldquo;Fibrin Clot Lysis by Thrombolytic Agents is Impaired in Newborns Due to a Low Plasminogen Concentration,&rdquo; <i>Thromb Haemost</i>, 1992, 68(3):325-30. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/1440499/pubmed\" target=\"_blank\" id=\"1440499\">1440499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bates SM, Greer IA, Middeldorp S, et al, &quot;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&quot; <i>Chest</i>, 2012, 141(2 Suppl):e691S-736S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/22315276/pubmed\" target=\"_blank\" id=\"22315276\">22315276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratincs&aacute;k A, Moore JW, El-Said HG. Low dose tissue plasminogen activator treatment for vascular thrombosis following cardiac catheterization in children: a single center experience. <i>Catheter Cardiovasc Interv</i>. 2013;82(5):782-785.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cada DJ, Levien T, and Baker DE, &ldquo;Alteplase,&rdquo; <i>Hospital Pharmacy</i>, 2002, 37(2): 148-54. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cathflo Activase (alteplase) [prescribing information]. South San Francisco, CA: Genentech, Inc; March 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choi M, Massicotte MP, Marzinotto V, et al, &ldquo;The Use of Alteplase to Restore Patency of Central Venous Lines in Pediatric Patients: A Cohort Study,&rdquo; <i>J Pediatr</i>, 2001, 139(1):152-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/11445811/pubmed\" target=\"_blank\" id=\"11445811\">11445811</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis SN, Vermeulen L, Banton J, et al, &ldquo;Activity and Dosage of Alteplase Dilution for Clearing Occlusions of Venous-Access Devices,&rdquo; <i>Am J Health Syst Pharm</i>, 2000, 57(11):1039-45. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/10876745/pubmed\" target=\"_blank\" id=\"10876745\">10876745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doyle E, Britto J, Freeman J, et al, &ldquo;Thrombolysis With Low Dose Tissue Plasminogen Activator,&rdquo; <i>Arch Dis Child</i>, 1992, 67(12):1483-4. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/1489229/pubmed\" target=\"_blank\" id=\"1489229\">1489229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farnoux C, Camard O, Pinquier D, et al, &ldquo;Recombinant Tissue-Type Plasminogen Activator Therapy of Thrombosis in 16 Neonates,&rdquo; <i>J Pediatr</i>, 1998, 133(1):137-40. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/9672527/pubmed\" target=\"_blank\" id=\"9672527\">9672527</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frazin BS, &ldquo;Maximal Dilution of Activase,&rdquo; <i>Am J Hosp Pharm</i>, 1990, 47(5):1016. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/2110773/pubmed\" target=\"_blank\" id=\"2110773\">2110773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Generali J and Cada DJ, &ldquo;Alteplase (t-PA) Bolus: Occluded Catheters,&rdquo; <i>Hospital Pharmacy</i>, 2001, 36(1):93-103. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2013;128(24):2622-2703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/24226806/pubmed\" target=\"_blank\" id=\"24226806\">24226806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. <i>N Engl J Med</i>. 2008; 359(13):1317-1329.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/18815396/pubmed\" target=\"_blank\" id=\"18815396\">18815396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hartmann J, Hussein A, Trowitzsch E, et al, &quot;Treatment of Neonatal Thrombus Formation With Recombinant Tissue Plasminogen Activator: Six Years Experience and Review of the Literature,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2001, 85(1):F18-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/11420316/pubmed\" target=\"_blank\" id=\"11420316\">11420316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hawkins JA, Scaife ES, Hillman ND, Feola GP. Current treatment of pediatric empyema. <i>Semin Thorac Cardiovasc Surg</i>. 2004;16(3):196-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/15619185/pubmed\" target=\"_blank\" id=\"15619185\">15619185</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaff MR, McMurtry MS, Archer SL, et al, &ldquo;Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association,&rdquo; <i>Circulation</i>, 2011, 123(16):1788-830.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/21422387/pubmed\" target=\"_blank\" id=\"21422387\">21422387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jauch EC, Saver JL, Adams HP Jr, et al, &ldquo;Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&rdquo; <i>Stroke</i>, 2013, 44(3):870-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/23370205/pubmed\" target=\"_blank\" id=\"23370205\">23370205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. <i>N Engl J Med</i>. 2002;347(15):1143-1150.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/12374874/pubmed\" target=\"_blank\" id=\"12374874\">12374874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leary SE, Harrod VL, de Alarcon PA, Reiss UM.  Low-dose systemic thrombolytic therapy for deep vein thrombosis in pediatric patients. <i>J Pediatr Hematol Oncol</i>. 2010;32(2):97-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/20118811/pubmed\" target=\"_blank\" id=\"20118811\">20118811</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leonhardt G, Gaul C, Nietsch HH, et al, &quot;Thrombolytic Therapy in Pregnancy,&quot; <i>J Thromb Thrombolysis</i>, 2006, 21(3):271-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/16683220/pubmed\" target=\"_blank\" id=\"16683220\">16683220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy M, Benson LN, Burrows PE, et al, &ldquo;Tissue Plasminogen Activator for the Treatment of Thromboembolism in Infants and Children,&rdquo; <i>J Pediatr</i>, 1991, 118(3):467-72. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/1900334 /pubmed\" target=\"_blank\" id=\"1900334 \">1900334 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li Y, Margraf J, Kluck B, et al, &quot;Thrombolytic Therapy For Ischemic Stroke Secondary to Paradoxical Embolism in Pregnancy: A Case Report and Literature Review,&quot; <i>Neurologist</i>, 2012, 18(1):44-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/22217616/pubmed\" target=\"_blank\" id=\"22217616\">22217616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chalmers E, Chan A, et al, &quot;Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&quot; <i>Chest</i>, 2008, 133(6 Suppl):887S-968S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/18574281/pubmed\" target=\"_blank\" id=\"18574281\">18574281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chan A, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 9th Edition. <i>Chest</i>, 2012, 141(2 Suppl):e737-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/22315277/pubmed\" target=\"_blank\" id=\"22315277\">22315277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nowak-Gottl U, Auberger K, Halimeh S, et al, &ldquo;Thrombolysis in Newborns and Infants,&rdquo; <i>Thromb Haemost</i>, 1999, 82 (Suppl 1):112-6. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/10695499/pubmed\" target=\"_blank\" id=\"10695499\">10695499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Gara PT, Kushner FG, Ascheim DD, et al, &quot;2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&quot; <i>Circulation</i>, 2013, 127(4):e362-425. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ponec D, Irwin D, Haire WD, et al, &ldquo;Recombinant Tissue Plasminogen Activator (Alteplase) for Restoration of Flow in Occluded Central Venous Access Devices: A Double-Blind Placebo-Controlled Trial - The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Efficacy Trial,&rdquo; <i>J Vasc Intern Radiol</i>, 2001, 12(8):951-5. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/11487675 /pubmed\" target=\"_blank\" id=\"11487675 \">11487675 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. <i>N Engl J Med</i>. 2011;365(6):518-526.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/21830966/pubmed\" target=\"_blank\" id=\"21830966\">21830966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Semba CP, Bakal CW, Calis KA, et al. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy. <i>J Vasc Interv Radiol</i>. 2000;11(3):279-287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/10735420/pubmed\" target=\"_blank\" id=\"10735420\">10735420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soylu H, Brand&atilde;o LR, and Lee KS, &quot;Efficacy of Local Instillation of Recombinant Tissue Plasminogen Activator for Restoring Occluded Central Venous Catheters in Neonates,&quot; <i>J Pediatr</i>, 2010, 156(2):197-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/19969306/pubmed\" target=\"_blank\" id=\"19969306\">19969306</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    St Peter SD, Tsao, K, Harrison C, et al. Thorascopic decortication vs tube thoracostomy with fibrinolysis for empyema in children: a prospective, randomized trial. <i>J Pediatr Surg</i>. 2009;44(1):106-111.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/19159726/pubmed\" target=\"_blank\" id=\"19159726\">19159726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. <i>N Engl J Med</i>. 1995;333(24):1581-1587.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/7477192/pubmed\" target=\"_blank\" id=\"7477192\">7477192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang M, Hays T, Balasa V, et al.  Low-dose tissue plasminogen activator thrombolysis in children. <i>J Pediatr Hematol Oncol</i>. 2003;25(5):379-386.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/12759624/pubmed\" target=\"_blank\" id=\"12759624\">12759624</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiner GM, Castle VP, DiPietro MA, et al, &ldquo;Successful Treatment of Neonatal Arterial Thromboses With Recombinant Tissue Plasminogen Activator,&rdquo; <i>J Pediatr</i>, 1998, 133(1):133-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alteplase-pediatric-drug-information/abstract-text/9672526/pubmed\" target=\"_blank\" id=\"9672526\">9672526</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13363 Version 119.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F132252\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F132253\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050935\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11431468\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050928\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F132234\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F132219\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050939\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471278\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F132245\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050938\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F132309\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F132306\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F132240\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F132223\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819738\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298716\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F132228\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F132230\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7872251\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050934\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F132222\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F132239\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1050943\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322973\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F132242\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13363|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=alteplase-drug-information\" class=\"drug drug_general\">Alteplase: Drug information</a></li><li><a href=\"topic.htm?path=alteplase-patient-drug-information\" class=\"drug drug_patient\">Alteplase: Patient drug information</a></li></ul></div></div>","javascript":null}